Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders

  • Elisabeth J. Van Bockstaele

Table of contents

  1. Front Matter
    Pages i-ix
  2. Elisabeth J. Van Bockstaele
    Pages 1-9
  3. Jahan Marcu, Linda Console-Bram, Mary E. Abood
    Pages 25-54
  4. Cecilia J. Hillard
    Pages 173-212
  5. Leyre Urigüen, Susana Esteban, Luís F. Callado, María Álvaro-Bartolomé, J. Javier Meana, Jesús A. García-Sevilla
    Pages 213-238
  6. Samir Haj-Dahmane, Roh-Yu Shen
    Pages 239-254
  7. Ahmet Dogrul, Melik Seyrek, Bulent Yalcin, Ahmet Ulugol
    Pages 277-295
  8. Colm M.P. O’Tuathaigh, Lieve Desbonnet, John L. Waddington
    Pages 297-323
  9. Back Matter
    Pages 325-337

About this book

Introduction

The past two decades have seen a tremendous growth in knowledge related to cannabinoid receptor signaling in brain.  In addition, the impact and consequences of cannabinoid modulation of monoaminergic circuits is steadily emerging demonstrating a significant interaction between these two systems in a variety of psychiatric (affective disorders) and neurological disorders (multiple sclerosis, pain). Despite increasing evidence from preclinical data suggesting that therapeutic use of cannabinoid-based drugs may outweigh any potential risks in certain serious medical conditions, the debate surrounding its widespread utility continues as regulatory concerns preclude a smooth transition of promising preclinical studies into clinical trial testing. This may persist in the near future as state and federal governments debate over regulation of medicinal applications of cannabis. Applications for medicinal cannabinoids that are already under investigation include the treatment of nausea, anorexia, neurodegeneration, inflammation, excitotoxicity and pain. The appetitive and anti-emetic properties of cannabinoids have led to the approval of their use in chemotherapy and AIDS patients.  There is growing evidence for therapeutic cannabinoid effects on inflammatory and excitotoxic cellular processes that are linked to epilepsy, Parkinson’s disease, amyotrophic lateral sclerosis, spasticity, and central nervous system injury. The chapters, herein, review and discuss current insights into the brain endocannabinoid system, cannabinoid receptor signaling on synaptic plasticity, potential therapeutic applications with a particular focus on endocannabinoid modulation of dopaminergic, noradrenergic and serotonergic circuitry. The potential for establishing cannabinoid-monoaminergic interactions as a novel target in the development of improved treatment strategies for psychiatric and neurological disorders is promising and will require future clinical studies to determine whether promising pre-clinical findings translate into new therapies.

Keywords

cannabinoid receptors cannabinoid therapy for neurological disorders cannabinoid therapy for psychiatric disorders endocannabinoids

Editors and affiliations

  • Elisabeth J. Van Bockstaele
    • 1
  1. 1., Department of NeuroscienceThomas Jefferson UniversityPhiladelphiaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4614-7940-6
  • Copyright Information Springer Science+Business Media New York 2013
  • Publisher Name Springer, New York, NY
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-1-4614-7939-0
  • Online ISBN 978-1-4614-7940-6
  • About this book